LFSCvsBBCETF Comparison
VS
F/m Emerald Life Sciences Innovation ETF (LFSC) belongs to the Life Sciences segment. Virtus LifeSci Biotech Clinical Trials ETF (BBC) is part of the Tomorrow's Treatments segment. LFSC's top 3 sector exposures are Healthcare and Sovereign. In contrast, BBC's top sector exposures are Healthcare LFSC is more expensive with a Total Expense Ratio (TER) of 0.79%, versus 0.65% for BBC. LFSC is up 23.23% year-to-date (YTD) with +$8M in YTD flows. BBC performs better with 28.33% YTD performance, and +$5M in YTD flows. Run a side-by-side ETF comparison of LFSC and BBC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
LFSC vs BBC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/24/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC BBC | +4.17%+1.30% | +20.39%+7.83% | +23.23%+28.33% | +82.30%+127.45% | n/a+114.85% | n/a+13.01% |
| Flows | LFSC BBC | +$2M+$83K | +$3M+$7M | +$8M+$5M | +$17M+$11M | -+$15M | -+$6M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC BBC | +26.23%+38.55% | +26.91%+35.78% | n/a+37.03% | n/a+39.66% |
| Max drawdown | LFSC BBC | -6.53%-11.64% | -16.25%-14.64% | n/a-54.25% | n/a-70.93% |
| Max drawdown duration | LFSC BBC | 20d54d | 168d60d | n/a340d | n/a1754d |
Trading data
LFSC | BBC | |
Last sale 7/24/2026 at 1:30 PM | $45.10 | $49.67 |
| Previous close 07/23/2026 | $45.46 | $50.31 |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexLFSC | BBC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
LFSC | BBC | |
|---|---|---|
| Last price | $45.10 | $49.67 |
| 1D performance | -0.79% | -1.27% |
| AuM | $123.48 M | $47.16 M |
| E/R | 0.79% | 0.65% |
Characteristics
LFSC | BBC | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Emerald Group | VIRTUS Investment Partners |
| Benchmark | - | LifeSci Biotechnology Clinical Trials Index |
| N° of holdings | 40 | 125 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | December 16, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
BBC
USA
85.4%
Other
14.6%
Sectors
LFSC
Healthcare
98.03%
Other
1.97%
BBC
Healthcare
95.19%
Other
4.81%
Diversification
LFSC
Total weight of top 15 holdings out of 15
73.24%
BBC
Total weight of top 15 holdings out of 15
14.01%
Top 15 holdings
Data as of June 30, 2026
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
BBC
uniQure NV
1.18%
REGENXBIO, Inc.
1.01%
Apogee Therapeutics, Inc.
0.99%
Monopar Therapeutics, Inc.
0.97%
Jade Biosciences, Inc.
0.94%
Aktis Oncology, Inc.
0.94%
MBX Biosciences, Inc.
0.94%
Biohaven Ltd.
0.90%
Kymera Therapeutics, Inc.
0.89%
Cullinan Therapeutics, Inc.
0.89%
SELLAS Life Sciences Group, Inc.
0.89%
Generate Biomedicines, Inc.
0.88%
Intellia Therapeutics, Inc.
0.87%
Nurix Therapeutics, Inc.
0.87%
4D Molecular Therapeutics, Inc.
0.86%
Frequently asked questions about LFSC and BBC
How have the LFSC and BBC ETFs performed in 2026?
As of July 24, 2026, LFSC is up 23.23% year-to-date (YTD), while BBC has returned 28.33%. That puts BBC better performer ahead so far this year.
Which ETF is attracting more investor money: LFSC or BBC?
Year-to-date, the LFSC ETF saw +$8M in flows, compared to +$5M for BBC.
Which ETF is more volatile: LFSC or BBC?
Over the past year, LFSC had a volatility of 26.91%, while BBC experienced 35.78%.
Which ETF is bigger: LFSC or BBC?
As of July 24, 2026, LFSC holds $123.48 M in assets under management (AUM), while BBC manages $47.16 M.
What sectors do the LFSC and BBC ETFs invest in?
LFSC leans toward sectors like Healthcare. Meanwhile, BBC focuses on Healthcare.
What are the top holdings of the LFSC ETF and BBC ETF?
LFSC top holdings include Travere Therapeutics, Inc., Cogent Biosciences, Inc. and LivaNova Plc. BBC holds in its top three: uniQure NV, REGENXBIO, Inc. and Apogee Therapeutics, Inc..
Which ETF is more diversified: LFSC or BBC?
LFSC holds 40 securities with 73.24% of its assets in the top 15. BBC has 125 securities and a top 15 weight of 14.01%.
Advertisement
Latest news about LFSC & BBC
Advertisement
